NCT07064122 - A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2025

Primary Completion Date

October 5, 2028

Study Completion Date

October 5, 2028

Conditions

Haematologic Neoplasms

Interventions

DRUG

AZD2962

AZD2962 will be administered orally once daily.

Trial Locations (17)

3000

Research Site, Melbourne

3084

Research Site, Heidelberg

3722

Research Site, Seoul

10002

Research Site, Taipei

28033

Research Site, Madrid

31008

Research Site, Pamplona

33612

Research Site, Tampa

37007

Research Site, Salamanca

46026

Research Site, Valencia

83301

Research Site, Kaohsiung City

141-0022

Research Site, Shinagawa-ku

910-1193

Research Site, Yoshida-gun

05505

Research Site, Seoul

08035

Research Site, Barcelona

NW1 2PG

Research Site, London

SE5 9RS

Research Site, London

M20 4BX

Research Site, Manchester